Financhill
Sell
20

IART Quote, Financials, Valuation and Earnings

Last price:
$12.67
Seasonality move :
4.98%
Day range:
$12.13 - $12.82
52-week range:
$11.60 - $32.66
Dividend yield:
0%
P/E ratio:
70.14x
P/S ratio:
0.60x
P/B ratio:
0.65x
Volume:
1.2M
Avg. volume:
1.3M
1-year change:
-56.86%
Market cap:
$983.8M
Revenue:
$1.6B
EPS (TTM):
-$0.38

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IART
Integra Lifesciences Holdings
$418.8M $0.58 -5.53% 241.78% $16.13
ISRG
Intuitive Surgical
$2.4B $1.96 16.8% 32.43% $575.78
LMAT
LeMaitre Vascular
$60.7M $0.54 11.88% 8.76% $104.50
OM
Outset Medical
$30.5M -$0.89 7.36% -90.13% $24.00
PODD
Insulet
$644.7M $1.10 25.31% -64.13% $332.35
TFX
Teleflex
$790.6M $3.37 2.91% 98.97% $157.62
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IART
Integra Lifesciences Holdings
$12.66 $16.13 $983.8M 70.14x $0.00 0% 0.60x
ISRG
Intuitive Surgical
$552.34 $575.78 $198B 80.99x $0.00 0% 23.01x
LMAT
LeMaitre Vascular
$82.20 $104.50 $1.9B 41.52x $0.20 0.88% 8.30x
OM
Outset Medical
$17.57 $24.00 $311.4M -- $0.00 0% 0.66x
PODD
Insulet
$325.03 $332.35 $22.9B 58.46x $0.00 0% 10.94x
TFX
Teleflex
$122.27 $157.62 $5.4B 38.57x $0.34 1.11% 1.90x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IART
Integra Lifesciences Holdings
54.74% 2.245 107.86% 0.57x
ISRG
Intuitive Surgical
-- 1.838 -- 3.81x
LMAT
LeMaitre Vascular
32.58% 2.765 8.86% 13.65x
OM
Outset Medical
35.65% 2.513 47.09% 6.60x
PODD
Insulet
56.03% 1.663 9.18% 3.24x
TFX
Teleflex
31.78% 0.827 30.89% 1.11x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IART
Integra Lifesciences Holdings
$194.4M -$15.5M -0.86% -1.88% -2.93% -$40.2M
ISRG
Intuitive Surgical
$1.5B $578.1M 15.82% 15.82% 25.66% $465M
LMAT
LeMaitre Vascular
$41.4M $12.6M 11.41% 13.74% 25.94% $7.7M
OM
Outset Medical
$11.1M -$16.4M -44.16% -140.06% -74.31% -$25.8M
PODD
Insulet
$409M $88.8M 15.79% 36.9% 10.07% $48.1M
TFX
Teleflex
$389.4M $130.3M 2.43% 3.41% 18.2% $43.1M

Integra Lifesciences Holdings vs. Competitors

  • Which has Higher Returns IART or ISRG?

    Intuitive Surgical has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 30.99%. Integra Lifesciences Holdings's return on equity of -1.88% beat Intuitive Surgical's return on equity of 15.82%.

    Company Gross Margin Earnings Per Share Invested Capital
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
    ISRG
    Intuitive Surgical
    64.69% $1.92 $17.2B
  • What do Analysts Say About IART or ISRG?

    Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 27.37%. On the other hand Intuitive Surgical has an analysts' consensus of $575.78 which suggests that it could grow by 4.24%. Given that Integra Lifesciences Holdings has higher upside potential than Intuitive Surgical, analysts believe Integra Lifesciences Holdings is more attractive than Intuitive Surgical.

    Company Buy Ratings Hold Ratings Sell Ratings
    IART
    Integra Lifesciences Holdings
    2 5 2
    ISRG
    Intuitive Surgical
    14 10 1
  • Is IART or ISRG More Risky?

    Integra Lifesciences Holdings has a beta of 1.268, which suggesting that the stock is 26.765% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

  • Which is a Better Dividend Stock IART or ISRG?

    Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IART or ISRG?

    Integra Lifesciences Holdings quarterly revenues are $382.7M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Integra Lifesciences Holdings's net income of -$25.3M is lower than Intuitive Surgical's net income of $698.4M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Intuitive Surgical's PE ratio is 80.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.60x versus 23.01x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IART
    Integra Lifesciences Holdings
    0.60x 70.14x $382.7M -$25.3M
    ISRG
    Intuitive Surgical
    23.01x 80.99x $2.3B $698.4M
  • Which has Higher Returns IART or LMAT?

    LeMaitre Vascular has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 18.39%. Integra Lifesciences Holdings's return on equity of -1.88% beat LeMaitre Vascular's return on equity of 13.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
    LMAT
    LeMaitre Vascular
    69.18% $0.48 $515.6M
  • What do Analysts Say About IART or LMAT?

    Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 27.37%. On the other hand LeMaitre Vascular has an analysts' consensus of $104.50 which suggests that it could grow by 27.13%. Given that Integra Lifesciences Holdings has higher upside potential than LeMaitre Vascular, analysts believe Integra Lifesciences Holdings is more attractive than LeMaitre Vascular.

    Company Buy Ratings Hold Ratings Sell Ratings
    IART
    Integra Lifesciences Holdings
    2 5 2
    LMAT
    LeMaitre Vascular
    3 6 0
  • Is IART or LMAT More Risky?

    Integra Lifesciences Holdings has a beta of 1.268, which suggesting that the stock is 26.765% more volatile than S&P 500. In comparison LeMaitre Vascular has a beta of 0.859, suggesting its less volatile than the S&P 500 by 14.076%.

  • Which is a Better Dividend Stock IART or LMAT?

    Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LeMaitre Vascular offers a yield of 0.88% to investors and pays a quarterly dividend of $0.20 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. LeMaitre Vascular pays out 32.65% of its earnings as a dividend. LeMaitre Vascular's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios IART or LMAT?

    Integra Lifesciences Holdings quarterly revenues are $382.7M, which are larger than LeMaitre Vascular quarterly revenues of $59.9M. Integra Lifesciences Holdings's net income of -$25.3M is lower than LeMaitre Vascular's net income of $11M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while LeMaitre Vascular's PE ratio is 41.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.60x versus 8.30x for LeMaitre Vascular. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IART
    Integra Lifesciences Holdings
    0.60x 70.14x $382.7M -$25.3M
    LMAT
    LeMaitre Vascular
    8.30x 41.52x $59.9M $11M
  • Which has Higher Returns IART or OM?

    Outset Medical has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of -86.66%. Integra Lifesciences Holdings's return on equity of -1.88% beat Outset Medical's return on equity of -140.06%.

    Company Gross Margin Earnings Per Share Invested Capital
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
    OM
    Outset Medical
    37.19% -$3.66 $264M
  • What do Analysts Say About IART or OM?

    Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 27.37%. On the other hand Outset Medical has an analysts' consensus of $24.00 which suggests that it could grow by 36.6%. Given that Outset Medical has higher upside potential than Integra Lifesciences Holdings, analysts believe Outset Medical is more attractive than Integra Lifesciences Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    IART
    Integra Lifesciences Holdings
    2 5 2
    OM
    Outset Medical
    3 2 0
  • Is IART or OM More Risky?

    Integra Lifesciences Holdings has a beta of 1.268, which suggesting that the stock is 26.765% more volatile than S&P 500. In comparison Outset Medical has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock IART or OM?

    Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outset Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Outset Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IART or OM?

    Integra Lifesciences Holdings quarterly revenues are $382.7M, which are larger than Outset Medical quarterly revenues of $29.8M. Integra Lifesciences Holdings's net income of -$25.3M is higher than Outset Medical's net income of -$25.8M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Outset Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.60x versus 0.66x for Outset Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IART
    Integra Lifesciences Holdings
    0.60x 70.14x $382.7M -$25.3M
    OM
    Outset Medical
    0.66x -- $29.8M -$25.8M
  • Which has Higher Returns IART or PODD?

    Insulet has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 6.22%. Integra Lifesciences Holdings's return on equity of -1.88% beat Insulet's return on equity of 36.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
    PODD
    Insulet
    71.88% $0.50 $3B
  • What do Analysts Say About IART or PODD?

    Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 27.37%. On the other hand Insulet has an analysts' consensus of $332.35 which suggests that it could grow by 2.25%. Given that Integra Lifesciences Holdings has higher upside potential than Insulet, analysts believe Integra Lifesciences Holdings is more attractive than Insulet.

    Company Buy Ratings Hold Ratings Sell Ratings
    IART
    Integra Lifesciences Holdings
    2 5 2
    PODD
    Insulet
    14 2 0
  • Is IART or PODD More Risky?

    Integra Lifesciences Holdings has a beta of 1.268, which suggesting that the stock is 26.765% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

  • Which is a Better Dividend Stock IART or PODD?

    Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IART or PODD?

    Integra Lifesciences Holdings quarterly revenues are $382.7M, which are smaller than Insulet quarterly revenues of $569M. Integra Lifesciences Holdings's net income of -$25.3M is lower than Insulet's net income of $35.4M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Insulet's PE ratio is 58.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.60x versus 10.94x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IART
    Integra Lifesciences Holdings
    0.60x 70.14x $382.7M -$25.3M
    PODD
    Insulet
    10.94x 58.46x $569M $35.4M
  • Which has Higher Returns IART or TFX?

    Teleflex has a net margin of -6.61% compared to Integra Lifesciences Holdings's net margin of 13.56%. Integra Lifesciences Holdings's return on equity of -1.88% beat Teleflex's return on equity of 3.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    IART
    Integra Lifesciences Holdings
    50.81% -$0.33 $3.4B
    TFX
    Teleflex
    55.58% $2.07 $6B
  • What do Analysts Say About IART or TFX?

    Integra Lifesciences Holdings has a consensus price target of $16.13, signalling upside risk potential of 27.37%. On the other hand Teleflex has an analysts' consensus of $157.62 which suggests that it could grow by 28.91%. Given that Teleflex has higher upside potential than Integra Lifesciences Holdings, analysts believe Teleflex is more attractive than Integra Lifesciences Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    IART
    Integra Lifesciences Holdings
    2 5 2
    TFX
    Teleflex
    0 11 0
  • Is IART or TFX More Risky?

    Integra Lifesciences Holdings has a beta of 1.268, which suggesting that the stock is 26.765% more volatile than S&P 500. In comparison Teleflex has a beta of 1.170, suggesting its more volatile than the S&P 500 by 17.034%.

  • Which is a Better Dividend Stock IART or TFX?

    Integra Lifesciences Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Teleflex offers a yield of 1.11% to investors and pays a quarterly dividend of $0.34 per share. Integra Lifesciences Holdings pays -- of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Teleflex's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios IART or TFX?

    Integra Lifesciences Holdings quarterly revenues are $382.7M, which are smaller than Teleflex quarterly revenues of $700.7M. Integra Lifesciences Holdings's net income of -$25.3M is lower than Teleflex's net income of $95M. Notably, Integra Lifesciences Holdings's price-to-earnings ratio is 70.14x while Teleflex's PE ratio is 38.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Integra Lifesciences Holdings is 0.60x versus 1.90x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IART
    Integra Lifesciences Holdings
    0.60x 70.14x $382.7M -$25.3M
    TFX
    Teleflex
    1.90x 38.57x $700.7M $95M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Salesforce Stock Be in 5 Years?
Where Will Salesforce Stock Be in 5 Years?

Salesforce (NYSE: CRM) just turned in a quarter that, on…

2 Ultra Safe Dividend Stocks to Buy Now
2 Ultra Safe Dividend Stocks to Buy Now

Historically, blue-chip dividend stocks have been good choices for periods…

Where Will Asana Stock Be in 5 Years?
Where Will Asana Stock Be in 5 Years?

Asana stock hasn’t given many investors on Wall Street any…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
31
REGN alert for May 31

Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.

Buy
55
RGC alert for May 31

Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.

Sell
42
AMBA alert for May 31

Ambarella [AMBA] is down 15.13% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock